Fosfomycin Tromethamine

Research use only, not for human use.

An antibiotic produced by Streptomyces fradiae.

An antibiotic produced by Streptomyces fradiae.(In Vitro):Fosfomycin sodium is an epoxy antibacterial agent. Compared with other antibacterial agents, it acts by inhibiting the early process of cell wall synthesis.Fosfomycin sodium has bactericidal activity against a variety of gram-negative and gram-positive pathogens, including broad-spectrum production β-Bacteria of lactamase and carbapenemase, and against S. aureus strains with an inhibition rate of 90%.Fosfomycin sodium displays extensive tissue penetration, can be used to research of infections of the CNS, soft tissues, bone, lungs, and abscesses.(In Vivo):Fosfomycin sodium (80 mg/kg; i.v.-i.v. or i.v.-p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes.

Fosfomycin tromethamine is an epoxy antibacterial agent. Compared with other antibacterial agents, it acts by inhibiting the early process of cell wall synthesis.Fosfomycin tromethamine has bactericidal activity against a variety of gram-negative and gram-positive pathogens, including broad-spectrum production β-Bacteria of lactamase and carbapenemase, and against S. aureus strains with an inhibition rate of 90%.Fosfomycin tromethamine displays extensive tissue penetration, can be used to research of infections of the CNS, soft tissues, bone, lungs, and abscesses.

Fosfomycin tromethamine (80 mg/kg; i.v.-i.v. or i.v.-p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes in rats.Pharmacokinetic of Fosfomycin Tromethamine in Rats. Animal Model:Fischer 344 ratsDosage:320 mg/kg Administration:Intramuscular injection, 5 schedules: 1 h, 0.5 h earlier than dibekacin, concomitantly, 0.5 h later and 1 h later; 11 days Result:Reduced polyuria, proteinuria, enzymes and cytosine caused by dibecacin (40 mg/kg), followed by the previous treatment.Animal Model:Dehydrated Wistar rat with acute renal failure (8-week-old) Dosage:120 mg/kg Administration:Intravenous injection; once Result:Recovered the exclusion rate of rats basically to normal, and improved the nephrotoxicity parameters. Protects proximal tubular lysosomes from aminoglycosides by inhibiting myeloid formation and protecting the integrity of lysosomal membrane of rats treated with double bekacin.

——

Others

Other Targets

Others

Inflammation/Immunology

Urinary tract infections

78964-85-9

259.19

C7H18NO7P

>98% (HPLC)

DMSO:196.8 mM;Water:196.8 mM

C[C@@H]1O[C@@H]1P(O)(O)=O.NC(CO)(CO)CO

——

(-20℃)

With Ice Pack

≥ 2 years